These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32275456)
1. Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil. Khattab WM; Zein El-Dein EE; El-Gizawy SA Drug Dev Ind Pharm; 2020 May; 46(5):795-805. PubMed ID: 32275456 [No Abstract] [Full Text] [Related]
2. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability. Nagaraj K; Narendar D; Kishan V Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908 [TBL] [Abstract][Full Text] [Related]
3. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. Alsofany JM; Hamza MY; Abdelbary AA AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766 [TBL] [Abstract][Full Text] [Related]
4. Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability. Komesli Y; Burak Ozkaya A; Ugur Ergur B; Kirilmaz L; Karasulu E Drug Dev Ind Pharm; 2019 Aug; 45(8):1292-1305. PubMed ID: 30986085 [TBL] [Abstract][Full Text] [Related]
5. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. B A; D N; Veerabrahma K Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):126-137. PubMed ID: 28290712 [TBL] [Abstract][Full Text] [Related]
6. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442 [TBL] [Abstract][Full Text] [Related]
7. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906 [TBL] [Abstract][Full Text] [Related]
8. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals. Jain S; Patel K; Arora S; Reddy VA; Dora CP Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656 [TBL] [Abstract][Full Text] [Related]
9. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs. Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438 [TBL] [Abstract][Full Text] [Related]
10. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859 [TBL] [Abstract][Full Text] [Related]
11. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension. Pandya NT; Jani P; Vanza J; Tandel H Colloids Surf B Biointerfaces; 2018 May; 165():37-44. PubMed ID: 29453084 [TBL] [Abstract][Full Text] [Related]
13. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation. Yousaf AM; Kim DW; Oh YK; Yong CS; Kim JO; Choi HG Int J Nanomedicine; 2015; 10():1819-30. PubMed ID: 25784807 [TBL] [Abstract][Full Text] [Related]
14. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Kaithwas V; Dora CP; Kushwah V; Jain S Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054 [TBL] [Abstract][Full Text] [Related]
15. Design, optimization and evaluation of poly-ε-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir. Ravi PR; Vats R; Dalal V; Gadekar N; N A Drug Dev Ind Pharm; 2015 Jan; 41(1):131-40. PubMed ID: 24180260 [TBL] [Abstract][Full Text] [Related]
16. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Albash R; El-Nabarawi MA; Refai H; Abdelbary AA Int J Nanomedicine; 2019; 14():6555-6574. PubMed ID: 31616143 [TBL] [Abstract][Full Text] [Related]
17. Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation. Jadhav P; Gokarna V; Deshpande V; Vavia P AAPS PharmSciTech; 2020 Sep; 21(7):254. PubMed ID: 32888102 [TBL] [Abstract][Full Text] [Related]
18. Trazodone Loaded Lipid Core Poly (ε-caprolactone) Nanocapsules: Development, Characterization and in Vivo Antidepressant Effect Evaluation. Elhesaisy N; Swidan S Sci Rep; 2020 Feb; 10(1):1964. PubMed ID: 32029776 [TBL] [Abstract][Full Text] [Related]
19. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Zhao L; Wei Y; Huang Y; He B; Zhou Y; Fu J Int J Nanomedicine; 2013; 8():3769-79. PubMed ID: 24124365 [TBL] [Abstract][Full Text] [Related]
20. Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats. Rahman MA; Harwansh RK; Iqbal Z Pharm Nanotechnol; 2019; 7(2):162-176. PubMed ID: 30919786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]